Replies to post #72261 on Cytodyn Inc (CYDY)

[TheBioTechG]

I was pretty upset with the “developments” regarding remdesivir today, but you might be right. Remdesivir has just set the standard of care for treatment of covid-19. Leronlimab’s data will be FAR SUPERIOR to remdesivir when we are able to release our results. The one thing that worries me is that since they will be first to approval, there’s a chance that subsequent therapeutics will be overlooked. Especially considering Gileads deep pockets, congressional power, and ability to market.

[misiu143]

And IMO when given very early , since it is affecting also positive way immune system , HCQ may show better results than Remdesivir if given a chance..

Lets do this type of study with EARLY disease.....

And we see less side effects in patients all together after 65 years of using HCQ in regular dose , than with aspirin ...and most possibly we will see less than with Remdesivir...

All IMO as always...